CClinicalTrials.gg
RecruitingNCT02869607Updated Aug 17, 2016

Institut Paoli Calmettes Breast Cancer Database

An observational study in Breast Cancer Diagnosis, sponsored by Institut Paoli-Calmettes. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-17.

Sponsored by Institut Paoli-Calmettes · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
45,000
Ages
18 Years and older
Sex
All
01

Study summary

Database of Institut Paoli-Calmettes patients diagnosed with breast cancer

02

Conditions studied

  • Breast Cancer Diagnosis

Browse trials for

03

In context

Breast Neoplasms

12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.

This study's planned enrollment of 45,000 is above the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Institut Paoli-Calmettes is the lead sponsor of 168 studies on the registry; 50 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with a diagnosis of Breat Cancer

Inclusion criteria

  • Patient with a diagnosis of breast cancer

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
45,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes

Groups and cohorts

  • Patients with breast cancer diagnosis

    Other: Data collection

Interventions

  • OtherData collection
06

What researchers measure

Primary outcomes

  1. Survival of patients with breast cancer

    Overall survival of all patients who come in the center

    Time frame: 10 years

Secondary outcomes

  1. Collection of patients characteristics

    Collection of characteristics of patients treated at Institut Paoli Calmettes in order to set up prospective and retrospective studies

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
  • Institut Paoli Calmettes
    Marseille, Bouches du Rhone 13009, France
    Recruiting
08

References and documents

Publications

  • Houvenaeghel G, de Nonneville A, Cohen M, Chopin N, Coutant C, Reyal F, Mazouni C, Gimbergues P, Azuar AS, Chauvet MP, Classe JM, Darai E, Martinez A, Rouzier R, de Lara CT, Lambaudie E, Barrou J, Goncalves A. Lack of prognostic impact of sentinel node micro-metastases in endocrine receptor-positive early breast cancer: results from a large multicenter cohort☆. ESMO Open. 2021 Jun;6(3):100151. doi: 10.1016/j.esmoop.2021.100151. Epub 2021 May 10. PubMed 33984674 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 17, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02869607
Lead sponsor
Institut Paoli-Calmettes
Responsible party
Sponsor
First posted
Aug 17, 2016
Start date
Jan 1995
Primary completion
Jan 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Aug 17, 2016

Study contacts

Dominique Genre, MD
Contact
drci.up@ipc.unicancer.fr
0033491223778
Lilian Laborde
Contact
labordel@ipc.unicancer.fr
0033491223778

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion